Update
$Clene (CLNN.US)$ Clene Inc. unveiled the preliminary design for RESTORE-ALS, a significant Phase 3 clinical trial of their CNM-Au8 30 mg treatment, at the 2024 NEALS Meeting. This development marks a pivotal moment in their research efforts, aiming to bring new treatment options for ALS patients. Investors and market enthusiasts may find this an exciting opportunity as the company progresses in its groundbreaking trial.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
